| scientific journal | Q5633421 |
| P6981 | ACNP journal ID | 2344812 |
| P8375 | Crossref journal ID | 52240 |
| P1058 | ERA Journal ID | 40025 |
| P8903 | HAL journal ID | 17316 |
| P236 | ISSN | 1745-8382 |
| 1745-8390 | ||
| P7363 | ISSN-L | 1745-8382 |
| P1055 | NLM Unique ID | 101261802 |
| P856 | official website | http://www.nature.com/nrrheum/archive/index.html |
| P10283 | OpenAlex ID | S4210180506 |
| P3181 | OpenCitations bibliographic resource ID | 67590 |
| P7662 | Scilit journal ID | 34174 |
| P1156 | Scopus source ID | 3100147502 |
| P495 | country of origin | United Kingdom | Q145 |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| P407 | language of work or name | English | Q1860 |
| P123 | publisher | Nature Portfolio | Q180419 |
| P1476 | title | Nature clinical practice rheumatology | |
| Nature Clinical Practice Rheumatology |
| Q46504592 | 5-HT3 receptor antagonist for the treatment of tendinopathy |
| Q57308006 | A biomarker by any other name.. |
| Q80543444 | A call for evidence-based quality measures: a goal worthy of pursuit |
| Q81184903 | A call for pragmatic treatment trials in rheumatoid arthritis |
| Q47250450 | A case highlighting the influence of knee joint effusion on muscle inhibition and size |
| Q40430356 | A case of Erdheim-Chester disease initially mistaken for Ormond's disease |
| Q46497011 | A case of adult-onset Satoyoshi syndrome with gastric ulceration and eosinophilic enteritis |
| Q52926335 | A case of axial undifferentiated spondyloarthritis diagnosis and management. |
| Q46189014 | A case of childhood-onset ankylosing spondylitis: diagnosis and treatment |
| Q54583801 | A case of destructive Wegener's granulomatosis complicated by cytomegalovirus infection. |
| Q38970397 | A case of human T lymphotropic virus type I-associated synovial swelling |
| Q40408368 | A case of macrophage activation syndrome successfully treated with anakinra |
| Q79390445 | A case of polymyalgia rheumatica, microscopic polyangiitis, and B-cell lymphoma |
| Q33379279 | A case of undifferentiated connective tissue disease: is it a distinct clinical entity? |
| Q57155441 | A critical look at the role of self-management for people with arthritis and other chronic diseases |
| Q53123279 | A growing crisis in confidence. |
| Q80167325 | A modest proposal |
| Q58210767 | A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis |
| Q80167158 | A new scoring system for Sjögren's syndrome? |
| Q81686518 | A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy |
| Q80167235 | A novel, disease-specific quality-of-life instrument for patients with SLE |
| Q80895677 | A paraneoplastic case of palmar fasciitis and polyarthritis syndrome |
| Q36611047 | A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis |
| Q54166430 | A woman with rheumatoid arthritis whose condition did not improve during pregnancy. |
| Q129553816 | ANCA-associated small vessel vasculitis: treatment with mycophenolate mofetil |
| Q53159092 | Access to clinical care via clinical trials: is it ethically possible? |
| Q37335863 | Activated B cells in autoimmune diseases: the case for a regulatory role |
| Q81770650 | Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis |
| Q37014112 | Adipokines as emerging mediators of immune response and inflammation. |
| Q34632947 | Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? |
| Q61912536 | Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship? |
| Q64045550 | Advocacy for persons with rare diseases: a strategy for creating influence |
| Q80210213 | Alefacept plus methotrexate for psoriatic arthritis |
| Q46305998 | Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss |
| Q80210220 | Alternatives to methotrexate for infliximab combination therapy in rheumatoid arthritis |
| Q82707882 | American College of Rheumatology recommendations for the treatment of RA: an issue of choices |
| Q46177207 | Anakinra for the treatment of neonatal-onset multisystem inflammatory disease |
| Q36897028 | Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis |
| Q79772043 | Anti-CCP versus anti-Sa antibodies for the diagnosis of RA |
| Q42060871 | Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells |
| Q80467018 | Anti-TNF switching: effect on outcomes in patients with RA |
| Q79772040 | Anti-dsDNA antibody testing in the clinic: Farr or ELISA? |
| Q79390440 | Antibodies against citrullinated proteins: which test is best? |
| Q79767344 | Antiplatelet versus anticoagulant therapy in patients with giant cell arteritis: which is best? |
| Q46456461 | Apple-picking in San Diego |
| Q37088887 | Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction? |
| Q81157159 | Are all DMARDs equivalent? |
| Q80167347 | Are anti-cyclic citrullinated peptide antibodies pathogenic in rheumatoid arthritis? |
| Q46561647 | Are cannabinoids a new treatment option for pain in patients with fibromyalgia? |
| Q79838860 | Are endothelin-receptor antagonists the preferred treatment for PAH associated with scleroderma? |
| Q81227751 | Are excellent systematic reviews of clinical trials useful for patient care? |
| Q82795986 | Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares? |
| Q58210778 | Are intra-articular injections of hylan more effective than injections of hyaluronic acid for knee osteoarthritis? |
| Q46630904 | Are modified-release corticosteroids good therapeutic options for patients with RA? |
| Q80167179 | Are occupational risk factors associated with markers of disease severity in patients with systemic scleroderma? |
| Q82286563 | Are patients with RA at increased risk of malignancy? |
| Q129555625 | Are patients with rheumatoid arthritis prone to accelerated atherosclerosis? |
| Q83290148 | Are static resting wrist splints beneficial in early RA? |
| Q39871833 | Are statins useful for treating vascular involvement in systemic sclerosis? |
| Q43641232 | Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus? |
| Q80212380 | Arthroscopic lavage of the knee with or without corticosteroids versus joint aspiration--which is best? |
| Q36585037 | Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? |
| Q51791813 | Available therapeutic options following failure of a first anti-TNF agent. |
| Q36956210 | B-cell lymphoproliferation in chronic inflammatory rheumatic diseases |
| Q36577391 | B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus |
| Q81344057 | Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis |
| Q51899246 | Behavioral changes in systemic lupus erythematosus are of an autoimmune nature. |
| Q36749763 | Behçet's syndrome: disease manifestations, management, and advances in treatment |
| Q37193616 | Beta-catenin in the race to fracture repair: in it to Wnt. |
| Q80167223 | Biochemical markers in osteoarthritis: will they measure up? |
| Q80467013 | Biologic agents and liver toxicity: an added concern or therapeutic opportunity? |
| Q36835538 | Biological markers in osteoarthritis |
| Q81975853 | Bisphosphonate treatment for patients with chronic nonbacterial osteomyelitis |
| Q126259784 | Bisphosphonates are cost-effective in steroid-treated patients with high fracture risk |
| Q80406971 | Bone, not cartilage, should be the major focus in osteoarthritis |
| Q36984865 | CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases |
| Q54215733 | Can corticosteroid therapy alter the course of nephritis in children with Henoch-Schönlein purpura? |
| Q36577448 | Can engineered cartilage transplants be used for treating rheumatic diseases? |
| Q80167205 | Can methotrexate replace cyclophosphamide in the treatment of a subset of Wegener's granulomatosis and microscopic polyangiitis? |
| Q80682960 | Can quantified salivary gland scintigraphy results aid diagnosis of patients with sicca symptoms? |
| Q80167175 | Can the adjusted mean SLEDAI-2K predict organ damage and coronary artery disease? |
| Q79888355 | Can treatment with risedronate benefit patients with knee osteoarthritis? |
| Q80854841 | Canadian recommendations for the management of spondyloarthritis address many different levels of patient care |
| Q50723731 | Carbonated apatite-induced arthropathy: a consideration in cases of polyarthritis. |
| Q37404476 | Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside |
| Q80167344 | Case studies with an educational purpose |
| Q80167214 | Catastrophic antiphospholipid syndrome |
| Q54310637 | Celecoxib--fewer gastrointestinal adverse events in patients with osteoarthritis. |
| Q83290154 | Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA? |
| Q80167141 | Challenges of predicting treatment response in patients with rheumatoid arthritis |
| Q49081187 | Childhood CNS vasculitis: a treatable cause of new neurological deficit in children |
| Q37072369 | Chronic nonmalignant pain: a challenge for patients and clinicians |
| Q46882551 | Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated? |
| Q39308044 | Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis. |
| Q57349626 | Clinical databases and biobanks for etiologic and therapeutic studies in rheumatoid arthritis |
| Q58490771 | Clinical research networks: a step towards evidence-based practice in pediatric rheumatology |
| Q56784322 | Clinical studies can be performed in an ethical manner |
| Q36577533 | Cognitive behavioral therapy for fibromyalgia |
| Q46110031 | Combination therapy for osteoporosis: a counter-regulatory conundrum |
| Q36897036 | Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs |
| Q81353141 | Combination versus monotherapy for patients with RA--are initial clinical benefits maintained over time? |
| Q81471253 | Commentary on the EULAR recommendations for the management of fibromyalgia |
| Q37303865 | Common mistakes in the clinical use of bone mineral density testing |
| Q80167277 | Comparing methods for the diagnosis of fibromyalgia |
| Q80210168 | Comparison of treatment-response criteria for juvenile idiopathic arthritis |
| Q30356453 | Complementary or alternative therapies for osteoarthritis. |
| Q82707876 | Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw |
| Q37204961 | Control of autoimmune diseases by the vitamin D endocrine system |
| Q33378474 | Conversion of discoid lupus to antiphospholipid syndrome and SLE. |
| Q28200286 | Coronary artery disease in patients with systemic lupus erythematosus |
| Q34013074 | Cryopyrinopathies: update on pathogenesis and treatment. |
| Q80761801 | Cytochrome P450 enzyme polymorphisms and treatment-related ovarian toxicity in patients with SLE |
| Q36577367 | Cytokine networks--towards new therapies for rheumatoid arthritis |
| Q80181694 | Cytokines and joint erosion in arthritis |
| Q83080003 | Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA |
| Q80167227 | Defining remission in rheumatoid arthritis based on the Disease Activity Score 28 |
| Q82224144 | Denosumab--a novel strategy to prevent structural joint damage in patients with RA? |
| Q45863411 | Diagnosis and treatment of vasculitis of the central nervous system in a patient with systemic lupus erythematosus |
| Q36577371 | Diagnosis of antiphospholipid syndrome |
| Q46796282 | Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis |
| Q36577453 | Diagnostic significance of ANCA in vasculitis |
| Q37282265 | Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy? |
| Q79932947 | Different physiotherapy regimens for back and neck pain |
| Q81184908 | Discussion of the 2007 British Society for Rheumatology guidelines for management of ANCA-associated vasculitis |
| Q80164608 | Do C-reactive protein levels help predict onset of rheumatoid arthritis in women? |
| Q81138145 | Do all drugs and treatments for rheumatoid arthritis have the same efficacy? |
| Q79487694 | Do antirheumatic drugs increase the risk of acute myocardial infarction? |
| Q50701704 | Do elevated red blood cell methotrexate polyglutamate levels predict methotrexate efficacy? |
| Q57458070 | Do exercise and advice help to improve the symptoms of subacute low back pain? |
| Q79390429 | Do genetic variations in the adenosine pathway affect patient response to methotrexate? |
| Q80860924 | Do high levels of IgA rheumatoid factor indicate a poor response to treatment with TNF inhibitors in patients with RA? |
| Q80533070 | Do high-sensitivity C-reactive protein levels help predict risk of cardiovascular disease in patients with osteoarthritis? |
| Q80167311 | Do nonsteroidal anti-inflammatory drugs accelerate disease progression in osteoarthritis? |
| Q44621678 | Do patients with RA receiving anti-TNF agents have an increased risk of surgical site infections? |
| Q44069497 | Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks? |
| Q81740932 | Do topical NSAIDs work? |
| Q80167150 | Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis? |
| Q38921803 | Do wedged insoles improve outcomes in patients with knee osteoarthritis? |
| Q81415894 | Does DMARD treatment slow or prevent development of RA in patients with UA? |
| Q80167154 | Does acupuncture help reduce pain in patients with fibromyalgia? |
| Q81044221 | Does acupuncture improve symptoms in patients with osteoarthritis who are awaiting knee replacement surgery? |
| Q46177488 | Does alendronate improve bone mineral density in patients with RA treated with glucocorticoids? |
| Q80167208 | Does anti-TNF therapy decrease the incidence of anterior uveitis in patients with ankylosing spondylitis? |
| Q45946531 | Does calcium supplementation increase bone mineral density in healthy children? |
| Q80228483 | Does calcium supplementation reduce the risk of osteoporotic fracture and bone loss? |
| Q79487700 | Does daily calcium supplementation reduce the risk of clinical fractures in elderly women? |
| Q39766809 | Does digital X-ray radiogrammetry help assess joint damage in patients with rheumatoid arthritis? |
| Q79390437 | Does diuretic use increase the risk of recurrent gout flares? |
| Q58490759 | Does early growth hormone therapy prevent glucocorticoid-associated growth retardation in children with JIA? |
| Q46584805 | Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis? |
| Q80167335 | Does flexion-distraction help treat chronic low back pain? |
| Q80167146 | Does hormone replacement therapy affect disease activity in patients with systemic lupus erythematosus? |
| Q36585041 | Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease? |
| Q54709135 | Does parathyroid hormone treatment affect fracture risk or bone mineral density in patients with osteoporosis? |
| Q61649744 | Does strength training affect the incidence and progression of knee osteoarthritis? |
| Q80429107 | Does the Health Assessment Questionnaire predict 5-year quality of life in early RA? |
| Q81591220 | Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis? |
| Q80093117 | Does treatment with DMARDs decrease the risk of cardiovascular disease in patients with RA? |
| Q80167197 | Doxycycline and osteoarthritis: what does it show us? |
| Q36667805 | Drug Insight: abatacept for the treatment of rheumatoid arthritis |
| Q37132710 | Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. |
| Q36577383 | Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases |
| Q36699052 | Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside |
| Q36749766 | Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation |
| Q37199641 | Drug insight: aggrecanases as therapeutic targets for osteoarthritis. |
| Q37174386 | Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases |
| Q36577467 | Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis |
| Q34736991 | Drug insight: autoimmune effects of medications-what's new? |
| Q28222352 | Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal |
| Q36775256 | Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? |
| Q30442932 | Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis |
| Q37139284 | Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis |
| Q80167126 | Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'? |
| Q36611042 | Early diagnosis of spondyloarthritis |
| Q80167299 | Early rheumatoid arthritis: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy |
| Q64941355 | Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids? |
| Q80167305 | Efficacy and safety of infliximab for the treatment of psoriatic arthritis |
| Q36835533 | Emerging targets of biologic therapies for rheumatoid arthritis |
| Q43042417 | Emerging viral infections and arthritis: the role of the rheumatologist |
| Q36815707 | Enhanced pharmacy review and community physiotherapy for knee pain in elderly patients |
| Q57751276 | Epidemiology and rheumatology: how can epidemiologists affect treatment strategies? |
| Q79176798 | Epidural corticosteroid injections for sciatica: placebo effect, injection effect or anti-inflammatory effect? |
| Q47810014 | Establishing the efficacy of traditional Chinese medicine |
| Q79716887 | Etanercept for patients with RA: more is not always better |
| Q79573318 | Etanercept plus sulfasalazine: added value in rheumatoid arthritis? |
| Q37187369 | Ethical issues in rheumatology clinical trials |
| Q80167290 | European rheumatology is advancing |
| Q50927443 | Even though T-cell-directed trials have been of limited success, is there reason for optimism? |
| Q34560542 | Evidence-based practice and practice-based evidence |
| Q81721386 | Fast forward for systemic lupus erythematosus clinical trials |
| Q79772037 | Fibromyalgia: 30 years of drug-seeking behavior |
| Q46266280 | First pregabalin and now duloxetine for fibromyalgia syndrome: closer to a brave new world? |
| Q81562831 | Focal and generalized bone loss in rheumatoid arthritis: separate or similar concepts? |
| Q79487698 | Frequency of COX2-inhibitor use in the clinic prior to market withdrawals |
| Q79772056 | Functional staging and surgical intervention of the elbow and shoulder joints in a patient with rheumatoid arthritis |
| Q51947261 | Genetics of osteoarthritis: early developmental clues to an old disease. |
| Q34819002 | Genomic and nongenomic effects of glucocorticoids |
| Q80167252 | Glucocorticoid therapy in rheumatoid arthritis: intra-articular injections versus systemic administration |
| Q57244851 | Glucosamine and chondroitin sulfate in knee osteoarthritis: where now? |
| Q46434526 | Glucosamine sulfate might have no effect on pain or structural changes associated with osteoarthritis |
| Q36585044 | Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease |
| Q37258206 | Growing pains: a noninflammatory pain syndrome of early childhood |
| Q80503511 | Hormone replacement therapy in systemic lupus erythematosus |
| Q79978030 | How can we improve adherence to therapy by patients with rheumatoid arthritis? |
| Q53410422 | How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA? |
| Q81449236 | How effective are the available treatments for mechanical neck disorder? |
| Q79926115 | How important is MRI for detecting early osteoarthritis? |
| Q81375944 | How important is collaboration between orthopedic surgeons and rheumatologists for optimizing the management of joint disease? |
| Q80860920 | How to assess low back pain |
| Q80243333 | How useful are synovial biopsies for the diagnosis of rheumatic diseases? |
| Q81909428 | Hypermobility: an important but often neglected area within rheumatology |
| Q59173852 | Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2 |
| Q80167201 | Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels? |
| Q80567325 | Identification of people with very early RA for optimal care: a public health challenge |
| Q83271920 | Imaging in osteoarthritis trials: useful or just expensive? |
| Q37404483 | Imaging the painful osteoarthritic knee joint: what have we learned? |
| Q80066093 | Imatinib for the treatment of rheumatic diseases |
| Q51140930 | Implant-related inflammatory arthritis. |
| Q80167144 | In-office imaging in the care of patients with rheumatoid arthritis |
| Q80167328 | Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide |
| Q52914312 | Inflammation, glucocorticoids and risk of cardiovascular disease. |
| Q81471248 | Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment? |
| Q80761797 | Infliximab treatment strategy: dose titration based on response in patients with RA |
| Q48268721 | Insight into SLE-related migraine using brain single-photon-emission computed tomography |
| Q36639873 | Interleukin 6: from bench to bedside |
| Q53211317 | International guidelines on access to biologic therapy: why the differences and which is best? |
| Q80210224 | Is MRI the best method to detect response to treatment in patients with ankylosing spondylitis? |
| Q80167255 | Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease? |
| Q81596739 | Is a step-down regimen more effective than a step-up regimen in the treatment of early rheumatoid arthritis? |
| Q80167229 | Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments? |
| Q80533066 | Is acupuncture an effective treatment for knee osteoarthritis? |
| Q80167338 | Is acupuncture more effective than sham acupuncture in relieving pain in patients with low back pain? |
| Q54239549 | Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis? |
| Q79633845 | Is anti-TNF therapy safe in patients with rheumatic disease who also have concurrent B or C chronic hepatitis? |
| Q80337158 | Is anti-tumor necrosis factor therapy effective in reducing uveitis flares in patients with spondyloarthropathies? |
| Q83407781 | Is arthroscopic surgery a beneficial treatment for knee osteoarthritis? |
| Q80167129 | Is assaying autoantibodies useful for diagnosing early rheumatoid arthritis? |
| Q80243401 | Is behavioral graded activity effective for the treatment of hip and knee osteoarthritis? |
| Q33336356 | Is computer-assisted management necessary for patients with early rheumatoid arthritis? |
| Q46192358 | Is denosumab better than alendronate in the treatment of osteoporosis? |
| Q80167272 | Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? |
| Q82286557 | Is long-term etanercept therapy safe and effective in patients with juvenile RA? |
| Q80715240 | Is methotrexate effective for the treatment of ankylosing spondylitis? |
| Q55042368 | Is milnacipran effective in treating pain in patients with fibromyalgia? |
| Q46573171 | Is mizoribine a new therapeutic agent for Sjögren's syndrome? |
| Q46266590 | Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus? |
| Q33998990 | Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis? |
| Q46397655 | Is pregabalin a safe and effective treatment for patients with fibromyalgia? |
| Q80051153 | Is rheumatoid arthritis a risk factor for cardiovascular disease? |
| Q46293827 | Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? |
| Q80167352 | Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment? |
| Q81944133 | Is rituximab suitable for use as a first-line biologic therapy for RA? |
| Q80997836 | Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease? |
| Q46104294 | Is spleen tyrosine kinase inhibition an effective therapy for patients with RA? |
| Q80228486 | Is surgery more effective than nonsurgical treatment for the management of patients with degenerative spondylolisthesis? |
| Q80167161 | Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease? |
| Q46707080 | Is teriparatide or alendronate the best treatment for glucocorticoid-induced osteoporosis? |
| Q80167284 | Is the lateral-view radiograph the optimal tool for assessing tibiofemoral joint space in knee osteoarthritis? |
| Q80167332 | Is the long-term use of systemic corticosteroids beneficial in the management of Behçet's syndrome? |
| Q48592231 | Is the risk of serious infections increased in patients with RA who receive treatment with antirheumatic drugs? |
| Q80167258 | Is the tuberculin skin test an accurate method of detecting tuberculosis in patients with rheumatoid arthritis? |
| Q43654377 | Is there a 'window of opportunity' for intervention to reduce risk of coronary artery disease in SLE? |
| Q36577517 | Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis? |
| Q46192354 | Is there a role for everolimus in the treatment of RA? |
| Q81944138 | Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis? |
| Q52912432 | Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? |
| Q81382549 | Is treatment with chondroitin efficacious for osteoarthritis? |
| Q80167181 | Is treatment with pulsed electromagnetic fields effective in patients with knee osteoarthritis? |
| Q80984939 | Is treatment with tumor necrosis factor inhibitors safe in pregnant patients? |
| Q80950301 | Issues concerning the biological repair of intervertebral disc degeneration |
| Q37335856 | Issues in the design of new clinical trials for rheumatoid arthritis therapeutics |
| Q81157154 | Kyphoplasty is not a nonpharmacologic management option for the minimization of fracture risk in osteoporosis |
| Q39845482 | Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis |
| Q79932943 | Long-term effects of early treatment in patients with rheumatoid arthritis |
| Q46194334 | Long-term effects of treatment with alendronate for patients with osteoporosis |
| Q40468437 | Lymphoma in a patient with systemic lupus erythematosus. |
| Q81798832 | MRI-detected bone marrow edema in early rheumatoid arthritis |
| Q46468081 | Maintaining remission in a patient with vasculitis |
| Q51035274 | Malar rash caused by metal allergy in a patient with systemic lupus erythematosus. |
| Q36577428 | Mechanisms and consequences of fibrosis in systemic sclerosis |
| Q36984877 | Mechanisms of Disease: angiogenesis in inflammatory diseases |
| Q36667812 | Mechanisms of Disease: genetics of fibromyalgia |
| Q36699060 | Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. |
| Q36667809 | Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. |
| Q36577483 | Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system |
| Q36577507 | Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus |
| Q36577527 | Mechanisms of Disease: the immunopathogenesis of spondyloarthropathies |
| Q36577375 | Mechanisms of Disease: the link between RANKL and arthritic bone disease |
| Q28281853 | Mechanisms of Disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis |
| Q36667816 | Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis |
| Q36749774 | Mechanisms of disease: Environmental factors in the pathogenesis of rheumatic disease |
| Q36577538 | Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis |
| Q36749770 | Mechanisms of disease: Molecular insights into aseptic loosening of orthopedic implants |
| Q36577542 | Mechanisms of disease: Transcription factors in inflammatory arthritis |
| Q36864025 | Mechanisms of disease: a 'DAMP' view of inflammatory arthritis |
| Q37088895 | Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism |
| Q36577423 | Mechanisms of disease: atherosclerosis in autoimmune diseases |
| Q37102156 | Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis |
| Q36577488 | Mechanisms of disease: genetics of Paget's disease of bone and related disorders |
| Q36984881 | Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes |
| Q36577443 | Mechanisms of disease: infection and spondyloarthritis. |
| Q36577405 | Mechanisms of disease: is osteoporosis the obesity of bone? |
| Q37072381 | Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis |
| Q36577418 | Mechanisms of disease: pain in fibromyalgia syndrome |
| Q80543447 | Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis--structure, chaos and senescence |
| Q36577472 | Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies |
| Q36577386 | Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis |
| Q34814114 | MicroRNAs, the immune system and rheumatic disease |
| Q41944676 | Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling |
| Q37288406 | Molecular effects of exercise in patients with inflammatory rheumatic disease |
| Q36639868 | Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials |
| Q36807468 | Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. |
| Q37335860 | Mycobacterial disease in patients with rheumatic disease |
| Q82795973 | NICE guidelines on anti-tumor necrosis factor therapy for RA |
| Q79888347 | NSAIDs and the risk of acute myocardial infarction |
| Q37243935 | Nature and functions of autoantibodies |
| Q57752098 | Nephrogenic systemic fibrosis: a new concern for rheumatologists |
| Q34054877 | Neurocognitive impairment in children and adolescents with systemic lupus erythematosus |
| Q36984870 | Neuroendocrine-immune interactions in synovitis |
| Q42539014 | Neuropsychiatric systemic lupus erythematosus reconsidered |
| Q37404485 | New approaches for managing antiphospholipid syndrome |
| Q28222356 | New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases |
| Q59031658 | New immune modulatory drugs for systemic lupus erythematosus—what can we expect? |
| Q37381676 | New insights into the pathogenesis and genetics of psoriatic arthritis |
| Q46227156 | New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability? |
| Q28263360 | Nonpharmacologic management of osteoporosis to minimize fracture risk |
| Q52855355 | Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment? |
| Q81375941 | Nontuberuclous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy |
| Q44332950 | Opioid therapy for the treatment of refractory pain in children with juvenile rheumatoid arthritis |
| Q31156123 | Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus |
| Q79317902 | Optimizing care for patients with rheumatic disease worldwide: a concept of global rheumatology |
| Q36577362 | Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? |
| Q81388951 | Oral versus parenteral administration of methotrexate for the treatment of active RA |
| Q80799296 | Osteoimmunology: a new area of rheumatology research |
| Q36984861 | Pain measurement in patients with low back pain. |
| Q39312046 | Painful knee locking caused by gouty tophi successfully treated with allopurinol |
| Q80210160 | Patient-centered outcomes: a bridge too far? |
| Q81368634 | Pediatric rheumatology--its own specialty |
| Q80167218 | Peptic ulcer disease in a patient with ankylosing spondylitis receiving a conventional nonsteroidal anti-inflammatory drug |
| Q80167171 | Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture |
| Q83407776 | Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP |
| Q81235302 | Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma |
| Q37355727 | Potential new drug targets for osteoporosis |
| Q80395750 | Prescription of glucosamine for osteoarthritis: does it work and is it safe? |
| Q81944141 | Primary prevention of systemic lupus erythematosus |
| Q36749778 | Primer: Demystifying risk--understanding and communicating medical risks |
| Q37102159 | Primer: SNP-associated studies and what they can teach us. |
| Q37150726 | Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know? |
| Q37014117 | Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages |
| Q36577498 | Primer: assessing the efficacy and safety of nonpharmacologic treatments for chronic rheumatic diseases |
| Q36984889 | Primer: challenges in randomized and observational studies |
| Q36735401 | Primer: comparative genetics of animal models of arthritis--a tool to resolve complexity |
| Q36925546 | Primer: epigenetics of autoimmunity |
| Q36775260 | Primer: establishing a clinical trial unit - regulations and infrastructure |
| Q36897041 | Primer: establishing a clinical trial unit--obtaining studies and patients |
| Q36956215 | Primer: genomic and proteomic tools for the molecular dissection of disease |
| Q37049033 | Primer: history and examination in the assessment of musculoskeletal problems |
| Q28263370 | Primer: inflammasomes and interleukin 1beta in inflammatory disorders |
| Q37049038 | Primer: making sense of T-cell memory. |
| Q36807481 | Primer: measuring the effects of treatment in clinical trials |
| Q36577410 | Primer: mechanisms of immunologic tolerance |
| Q36897046 | Primer: pitfalls of aspiration and injection |
| Q36984884 | Primer: signal transduction in rheumatic disease--a clinician's guide |
| Q37070233 | Primer: strengths and weaknesses of meta-analysis. |
| Q36864035 | Primer: the fallacy of subgroup analysis |
| Q36925542 | Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases |
| Q79751082 | Prognostic indicators in lateral epicondylitis: is it possible to predict pain outcomes? |
| Q46423496 | Progressive arm and leg stiffness in a patient with chronic renal impairment. |
| Q36577492 | Prospects for disease modification in osteoarthritis. |
| Q81484114 | Proton-pump inhibitors as a protective treatment for high-risk patients receiving treatment with NSAIDs |
| Q37014104 | Psoriatic disease--from skin to bone |
| Q53475183 | Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. |
| Q80371153 | Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo? |
| Q80167286 | Quality of life after shoulder arthroplasty-total shoulder arthroplasty versus hemiarthroplasty |
| Q83080013 | RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists |
| Q40440524 | Rapid immunodiagnosis of tuberculosis in a woman receiving anti-TNF therapy |
| Q37078072 | Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? |
| Q36925538 | Regional pain syndrome: clinical characteristics, mechanisms and management |
| Q52915496 | Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. |
| Q42572794 | Rheumatoid arthritis in a mouse? |
| Q80167280 | Rheumatoid arthritis-is methotrexate re-employment an effective treatment option? |
| Q79862455 | Rheumatology in the Asia Pacific region--opportunities and challenges |
| Q80997995 | Rheumatology in the current era: the challenge of success |
| Q80406967 | Rheumatology without borders |
| Q54806488 | Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism |
| Q36639862 | Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor |
| Q36735392 | Risk factors and prognostic factors of hip and knee osteoarthritis |
| Q81516073 | Risk in clinical trials |
| Q52924018 | Risk of serious bacterial infection: treatment with anti-TNF versus methotrexate. |
| Q46732663 | Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma |
| Q80167293 | Science as experiment; science as observation |
| Q36585033 | Screening for frailty among seniors in clinical practice. |
| Q82224150 | Screening for osteoporosis in men: comment on the American College of Physicians clinical guidelines |
| Q79573313 | Self-reporting instruments in rheumatoid arthritis |
| Q126259788 | Serum leptin levels might be a useful measure of disease activity in patients with RA |
| Q33255239 | Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis |
| Q80799458 | Should all patients with systemic lupus erythematosus receive cardioprotection with statins? |
| Q46878674 | Should aspirin be used as a preventive therapy for thrombosis in patients with antiphospholipid antibodies? |
| Q79686831 | Should induction therapy with high-dose glucocorticoids be the standard treatment for all patients with giant cell arteritis? |
| Q81382553 | Should infliximab be used to help maintain glucocorticosteroid-induced remission in patients with giant cell arteritis? |
| Q80682965 | Should opioids be prescribed to treat patients with osteoarthritis? |
| Q46984581 | Should patients with RA be aggressively monitored for hypertension? |
| Q80093114 | Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs? |
| Q80167267 | Socioeconomics of back pain |
| Q80167270 | Spinal inflammation in ankylosing spondylitis--how and why should it be measured by MRI? |
| Q36699047 | Strategies for primary and secondary prevention of Lyme disease |
| Q36639857 | Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes |
| Q39276118 | Strengthening resilience capacity might light the way to a brighter future for patients with fibromyalgia |
| Q81227747 | Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis |
| Q57216480 | Subclinical carotid atherosclerosis in a patient with systemic lupus erythematosus |
| Q80167322 | Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol |
| Q37107862 | Surgery Insight: orthopedic treatment options in rheumatoid arthritis |
| Q36639851 | Switching tumor necrosis factor inhibitors: an opinion |
| Q37072377 | Synoviolin, protein folding and the maintenance of joint homeostasis |
| Q36577397 | Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome |
| Q36577432 | Systemic lupus erythematosus--2005 annus mirabilis? |
| Q126264746 | T-cell immunization is feasible for patients with RA |
| Q36577464 | T-cell-targeted therapies in rheumatoid arthritis |
| Q36577523 | Technology Insight: adult stem cells in cartilage regeneration and tissue engineering |
| Q37088891 | Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease |
| Q36611052 | Technology Insight: imaging of low back pain |
| Q36699056 | Technology Insight: the role of color and power Doppler ultrasonography in rheumatology |
| Q37163015 | Technology insight: adult mesenchymal stem cells for osteoarthritis therapy |
| Q36735396 | Technology insight: can autoantibody profiling improve clinical practice? |
| Q36577437 | Technology insight: gene transfer and the design of novel treatments for rheumatoid arthritis. |
| Q37145844 | Technology insight: noninvasive assessment of bone strength in osteoporosis |
| Q36807476 | Technology insight: tools for research, diagnosis and clinical assessment of treatment in idiopathic inflammatory myopathies |
| Q80210209 | Ten key recommendations for the management of ankylosing spondylitis |
| Q37072372 | Tendinopathy--from basic science to treatment |
| Q80632492 | Testing for antibodies to cyclic citrullinated peptides and rheumatoid factor--what is best for early RA? |
| Q80406975 | Thalidomide for rheumatic disease: the best of both worlds? |
| Q80395753 | The European League Against Rheumatism guidelines for early arthritis |
| Q28219758 | The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients |
| Q36925535 | The assessment of ankylosing spondylitis in clinical practice. |
| Q34710594 | The battle between anti-cyclic citrullinated peptide and rheumatoid factor tests--a winner at last? |
| Q80167264 | The benefits and costs of biologic registers |
| Q82092557 | The cardiovascular threat of lupus |
| Q64111331 | The challenges of determining RA disease activity and remission in clinical practice |
| Q36897032 | The changing epidemiology of gout |
| Q45868895 | The clinical impact of neuropsychiatric manifestations in early systemic lupus erythematosus |
| Q37381684 | The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease |
| Q40254519 | The future of imaging in monitoring biologic therapy |
| Q46269796 | The future of specialty care in the US. |
| Q33276525 | The health assessment questionnaire in routine clinical practice |
| Q80972746 | The importance of literacy in research and in practice |
| Q79716884 | The importance of recognizing scleroderma-type disorders in clinical practice |
| Q48407432 | The lack of impact of the 'impact factor' in clinical medicine |
| Q36577478 | The management of Sjögren's syndrome |
| Q36577380 | The management of pediatric systemic lupus erythematosus |
| Q37355730 | The molecular basis of pain and its clinical implications in rheumatology |
| Q79487693 | The pitfalls in the development of biologic therapy |
| Q37355734 | The role of ADAMTS-7 and ADAMTS-12 in the pathogenesis of arthritis. |
| Q37255748 | The role of Wnt proteins in arthritis |
| Q83271914 | The uncertain pathway to new therapeutics for SLE |
| Q37278012 | Therapeutic advances in rheumatology with the use of recombinant proteins |
| Q36577459 | Therapeutics of Wegener's granulomatosis |
| Q37113440 | Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus |
| Q34560547 | Therapy Insight: fibromyalgia--a different type of pain needing a different type of treatment |
| Q36577503 | Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis |
| Q36611056 | Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus |
| Q37118482 | Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease |
| Q36577546 | Therapy insight: The recognition and treatment of retinal manifestations of systemic vasculitis |
| Q36807472 | Therapy insight: guidelines for selection of contraception in women with rheumatic diseases |
| Q36984895 | Therapy insight: how the gut talks to the joints--inflammatory bowel disease and the spondyloarthropathies |
| Q36775251 | Therapy insight: scleritis and its relationship to systemic autoimmune disease. |
| Q37199644 | Therapy insight: the changing spectrum of rheumatic disease in HIV infection |
| Q36864030 | Therapy insight: the use of antirheumatic drugs during nursing |
| Q37355736 | There's more to life than everyday function: the challenge of measuring social role participation in ankylosing spondylitis. |
| Q28211887 | Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties |
| Q51895499 | Tight control for the management of RA--a therapeutic approach worth pursuing. |
| Q83407791 | Time for new outcome measures in hand osteoarthritis? |
| Q37014108 | Tobacco smoking and autoimmune rheumatic diseases |
| Q80167302 | Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis |
| Q37381681 | Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative |
| Q80984935 | Treatment of acute gout-like arthritis in an emergency setting: prednisolone versus indomethacin |
| Q36775248 | Treatment of chronic pain in pediatric rheumatic disease |
| Q81353139 | Treatment with TNF inhibitors for uveitis associated with juvenile idiopathic arthritis |
| Q80167191 | Truth in clinical medicine |
| Q79487696 | Tumor necrosis factor antagonists and cancer in patients with rheumatoid arthritis |
| Q37163019 | Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus |
| Q81686522 | Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren's syndrome |
| Q79862464 | Unresolved issue: should patients with RA and a history of malignancy receive anti-TNF therapy? |
| Q37255744 | Update on the management of lupus nephritis: let the treatment fit the patient |
| Q48491966 | Utility of cognitive behavioral therapy as a treatment for insomnia in patients with fibromyalgia |
| Q37293144 | Vitamin D and musculoskeletal health |
| Q81427840 | What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate? |
| Q80641315 | Why do some biologic agents induce psoriasis or psoriasiform lesions? |
| Q81270825 | Why do we need noncommercial, investigator-initiated clinical trials? |
| Q80657468 | Why is the management of fibromyalgia syndrome so difficult for rheumatologists? |
| Q36577512 | Will arthritis gene therapy become a clinical reality? |
| Q37280613 | Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis |
Search more.